Project Grant R01HL179220
Award Date 8/1/26
Completion Date 4/30/31
Dollars Obligated $792K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $1.738 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate serotonergic circuit mechanisms that enhance upper airway tone and respiration in patients receiving opioids and experiencing sleep-disordered breathing. The research identifies how brain serotonergic cell subtypes can offset adverse respiratory effects of opioids without compromising...
- The National Heart, Lung, and Blood Institute awarded the University of California Irvine a project grant of $214,071 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research investigating the cardiac response to obstructive sleep apnea through an in-vitro heart-on-a-chip platform combined with intermittent hypoxia protocols. The research will develop and validate physiologically relevant intermittent hypoxia protocols using endothelial...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $166,248 on September 26, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research triangulating causal effects of sleep, inflammation, and cardiometabolic disease. The research will identify oxylipin biomarkers associated with sleep problems—including insomnia, sleep apnea, and short sleep duration—and their relationship to cardiometabolic disease. The study...
- The National Heart Lung and Blood Institute awarded New York University School of Medicine $795,421 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-specific responses to obstructive sleep apnea therapies. The research examines how oxidative stress mediates cardiovascular harm from obstructive sleep apnea, with particular focus on sex differences in treatment response. The study tests N-acetylcysteine, an antioxidant precursor that...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $1.542 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to improve understanding of sleep apnea pathogenesis using novel imaging techniques during sleep. The research combines drug-induced sleep endoscopy (DISE) with dynamic magnetic resonance imaging (MRI) to characterize upper airway anatomy and the mechanisms of airway collapse during sleep. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, Irvine a $1,296,660 Project Grant on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a comprehensive "Bed to Bench" evaluation of the cardiac and vascular impact of obstructive sleep apnea (OSA). The research will address critical knowledge gaps in understanding the mechanistic pathways linking OSA to...
- The National Heart Lung and Blood Institute awarded $1.449 million to the University of North Carolina at Chapel Hill on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837, R01HL177199) to conduct a multi-site prospective study examining the prevalence, clinical impact, and treatment response of sleep-associated hypoxemia in adults with sickle cell anemia. The study enrolls adult patients with homozygous sickle cell anemia (SCA) at four institutions—University of...
- The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals $780,960 on July 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate treatment adherence interventions for young adults with obstructive sleep apnea. The award funds a five-year randomized controlled trial testing two interventions designed to improve continuous positive airway pressure (CPAP) treatment adherence among young adults ages 18–25. The research addresses a documented...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital $171,600 on September 1, 2026, under CFDA 93.837 (Cardiovascular Diseases Research) to support career development and mentored research in pediatric obstructive sleep apnea diagnostics. The award funds the recipient investigator's training in three areas: predictive modeling and machine learning, advanced physiological signal analysis, and implementation science for translating research into clinical...
- The National Institute on Drug Abuse awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) $574,954 in funding for Project Grant R01DA061865 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The project investigates homeostatic mechanisms of the brain's locus coeruleus noradrenergic system in opioid use disorder as a contributor to opioid-induced sleep disturbances. Sleep dysfunction in opioid use disorder drives...